Joint Bookrunner
Kempen & Co is pleased to announce that it acted as Joint Bookrunner in Molecular Partners’ CHF 80.2m Accelerated Bookbuild Offering
Molecular Partners is a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin® therapeutics, designed to address challenges current modalities cannot. The company has compounds in various stages of clinical and preclinical development with a focus on oncology. Molecular Partners has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics across multiple therapeutic areas.